Drug Approval | March 09, 2024
USFDA conducts inspection at Alembic Pharmaceuticals' Panelav oncology formulation facility
The company will provide comprehensive response to USFDA for the observations
The company will provide comprehensive response to USFDA for the observations
Cipla completes transfer of Generics Business Undertaking
Eugia Pharma Specialities restarts production at terminally sterilized product lines
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The company intends to respond to the two minor observations within the stipulated time
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The company has received Form 483 with three observations
Subscribe To Our Newsletter & Stay Updated
